2211 related articles for article (PubMed ID: 28017734)
1. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
2. CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.
Tamari R; Chung SS; Papadopoulos EB; Jakubowski AA; Hilden P; Devlin SM; Goldberg JD; Perales MA; Ponce DM; Sauter CS; Maloy MA; Herman DY; Klimek V; Young JW; O'Reilly RJ; Giralt SA; Castro-Malaspina H
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2106-2114. PubMed ID: 26187863
[TBL] [Abstract][Full Text] [Related]
3. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34
Tamari R; Oran B; Hilden P; Maloy M; Kongtim P; Papadopoulos EB; Rondon G; Jakubowski AA; Andersson BS; Devlin SM; Ahmed S; Popat UR; Ponce D; Chen J; Sauter C; Young JW; de Lima M; Perales MA; O'Reilly RJ; Giralt SA; Champlin RE; Castro-Malaspina H
Biol Blood Marrow Transplant; 2018 May; 24(5):1079-1087. PubMed ID: 29325829
[TBL] [Abstract][Full Text] [Related]
5. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
[TBL] [Abstract][Full Text] [Related]
7. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
8. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
9. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
[TBL] [Abstract][Full Text] [Related]
10. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M
Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro J; Roldán E; Piñana JL; Barba P; Chorão P; Quintero A; Hernani R; Ortí G; Lorenzo JI; Balaguer-Roselló A; Salamero O; Fox L; Solves P; Gómez I; Guerreiro M; Hernández Boluda JC; Sanz G; Solano C; Sanz MÁ; Valcárcel D; Sanz J
Eur J Haematol; 2021 Jan; 106(1):114-125. PubMed ID: 33025625
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
13. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
15. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
[TBL] [Abstract][Full Text] [Related]
17. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation.
Mohty M; Bilger K; Jourdan E; Kuentz M; Michallet M; Bourhis JH; Milpied N; Sutton L; Jouet JP; Attal M; Bordigoni P; Cahn JY; Sadoun A; Ifrah N; Guyotat D; Faucher C; Fegueux N; Reiffers J; Maraninchi D; Blaise D
Leukemia; 2003 May; 17(5):869-75. PubMed ID: 12750699
[TBL] [Abstract][Full Text] [Related]
18. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303.
Devine SM; Carter S; Soiffer RJ; Pasquini MC; Hari PN; Stein A; Lazarus HM; Linker C; Stadtmauer EA; Alyea EP; Keever-Taylor CA; O'Reilly RJ
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1343-51. PubMed ID: 21320619
[TBL] [Abstract][Full Text] [Related]
19. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
[TBL] [Abstract][Full Text] [Related]
20. High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Czerw T; Labopin M; Schmid C; Cornelissen JJ; Chevallier P; Blaise D; Kuball J; Vigouroux S; Garban F; Lioure B; Fegueux N; Clement L; Sandstedt A; Maertens J; Guillerm G; Bordessoule D; Mohty M; Nagler A
Oncotarget; 2016 May; 7(19):27255-66. PubMed ID: 27036034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
